Table C-4. Risk of bias assessment for observational studies

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, Year  Trial Name  Design | Was the sample size adequate? | Were groups recruited from the same source population? | Were groups recruited over the same time period? | Were inc/exc criteria applied equally for all groups? | Were groups similar at baseline? | What was the overall attrition? | What was the differential attrition? | Did the study have overall high attrition or differential attrition raising concern for bias? | Was intervention fidelity adequate? |
| Coller, 2011155  Prospective cohort | Yes | NR/CND | NR/CND | Yes | Yes | 32 | <1 | Yes | NR/CND |
| Kim, 2009156  Prospective cohort | No | Yes | NR/CND | Yes | No | 49 | 22 | Yes | NR/CND |
| Narayana, 2008157  Prospective cohort | Yes | Yes | Yes | Yes | Yes, for the few characteristics reported | 29 | CND exact number, but appears to be about 20% higher in the NTX and ACA groups than the TOP group | Yes | NR/CND |
| Mutschler, 2012158  Prospective cohort | Yes | Yes | NR/CND | NR/CND | Yes | NR/CND | NR/CND | NR/CND | NR/CND |
| Rubio, 2002159  Prospective cohort | No | NR/CND | NR/CND | NR/CND | NR/CND | NR/CND | NR/CND | NR/CND | NR/CND |

Abbreviations: ACA = acamprosate; CND = cannot determine; NR = not reported; NTX = naltrexone; TOP = topiramate